Implementation of the Medicinal Cannabis Scheme in New Zealand

Making Education Easy

Authors:

Rychert M et al.

November 20, 2024

Summary:

While New Zealand’s Medicinal Cannabis Scheme (MCS) has successfully established a domestic production sector, reduced prices and provided alternatives to illegal supply, there may also be unintended negative consequences. These were the findings of an analysis of the MCS since implementation in 2020. The analysis found that the quarterly supply of medicinal cannabis products has increased fourteenfold since implementation, with most products now THC-dominant rather than CBD and in the form of dried cannabis flower rather than oral liquids/oils. Prices of products have declined to be comparable with the illegal market. While specialised private cannabis clinics have expanded patient access, inequities persist due to expense, disproportionately affecting Māori and those on lower incomes.

Comment:

Personally, I’ve had a mixed experience in prescribing medicinal cannabis, which is reflected in these findings. People may request it after hearing from others or seeing it in the media, but the majority will stop if ineffective, or when cost becomes too much. For the latter, although they prefer “legally” prescribed forms, they will purchase it illegally because it’s cheaper.

Reference: N Z Med J. 2024;137(1604):73-86.

Independent commentary by Dr. Matire Hardwood

Dr Matire Harwood (Ngapuhi) has worked in Hauora Māori, primary health and rehabilitation settings as clinician and researcher since graduating from Auckland Medical School in 1994. She also holds positions on a number of boards, committees and advisory groups including the Health Research Council. Matire lives in Auckland with her whānau including partner Haunui and two young children Te Rangiura and Waimarie.

Research Review publications are intended for New Zealand health professionals.

Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.